Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Gemcitabine and Erlotinib in Operable Pancreatic Adenocarcinoma
NCT00733746Phase 2Completed
- Sponsor
- Cancer and Leukemia Group B
- Start
- Apr 2009
- Primary completion
- Nov 2015
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 2, open-label, single-arm trial of erlotinib and gemcitabine in pancreatic adenocarcinoma (PDAC), sponsored by Cancer and Leukemia Group B. Primary endpoint: Overall Survival at 2 Years. Started Apr 2009; status: completed.
02
Drugs
erlotinibgemcitabine
03
Conditions
pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT00733746.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00733746.